IN-VITRO STUDY OF ANTI-DIABETIC, ANTI-CANCER AND ANTI-UROLITHIATIC ACTIVITY OF DIFFERENT EXTRACTS OF PROSOPIS JULIFLORA SEEDS
AbstractPlants and their parts are used to treat many infectious diseases due to the presence of phytoconstituents and avoid some side effects. The present study evaluated the phytochemicals, anti-diabetic, anti-urolithiatic, and anti-cancer activities of Prosopis juliflora seeds in various solvents such as aqueous, ethanol, and 85% ethanol. The preliminary works revealed the presence of secondary metabolites likes alkaloid, phenol, saponin, tannin, phytosterol and flavonoids. The work focused on the anti-diabetic properties of the extract by α-amylase, α-glucosidase methods. In-vitro anti-urolithiatic activity by titrimetric method showed that there was maximum activity, and its effect was compared with the standard drug cystone. The MTT assay was used to screen the crude extracts and the isolated compounds to assess their toxicity. The aqueous extracts of Prosopis juliflora seeds showed the inhibition effects of the cancer cell lines (MCF7), while there was no effect on the growth of normal cells. Such selective effects were found to be time-dependent. With respect to concentration (25 µg/ml, 50 µg /ml, 100 µg /ml, 250 µg /ml and 500 µg /ml,) of extract were evaluated in triplicates by serial dilution. Among these, 500 µg /ml of ethanol extract was the most effective in producing percentage growth inhibition. The results showed that the aqueous extract significantly inhibited the (MCF7) cancer cell lines. So, seeds of Prosopis juliflora extract can be exploding further to produce active herbal principles for therapeutic use.
Article Information
28
2101-2108
1198 KB
503
English
IJPSR
D. Leema Rose Mary *, P. M. Arie Arockianathan, A. Lawrance and A. Edwina Sherley Felicita
PG & Research Department of Biochemistry, St. Joseph’s College of Arts and Science (Autonomous), Cuddalore, Tamil Nadu, India.
samlee5700@gmail.com
16 August 2021
19 September 2021
21 September 2021
10.13040/IJPSR.0975-8232.13(5).2101-08
01 May 2022